Nancy Dorman
Family · Interlochen, MINPI 1750801940
Payments from drug & device makers
Across 141 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$765
- GSK$447
- Novo Nordisk$223
- AstraZeneca$182
- Amgen$139
- Astellas Pharma US Inc$106
- plus $543 from 13 others
What the payments were for
- Food & beverage$2,405100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $765 |
| GSK | 21 | $447 |
| Novo Nordisk | 15 | $223 |
| AstraZeneca | 12 | $182 |
| Amgen | 7 | $139 |
| Astellas Pharma US Inc | 6 | $106 |
| Lilly USA, LLC | 6 | $103 |
| Exact Sciences | 4 | $85 |
| Pfizer | 4 | $79 |
| Boehringer Ingelheim | 3 | $63 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Dexcom, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Corium, LLC | 2 | $23 |
| Alkermes, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
How this compares
$2,405 in reported general payments places this provider in the 85th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 35 | $37,332 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $29,943 |
| EliquisApixaban | 20 | $24,990 |
| JanuviaSitagliptin Phosphate | 12 | $15,649 |
| OzempicSemaglutide | 14 | $15,140 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $5,089 |
| Lurasidone Hcl | 18 | $3,926 |
| Levothyroxine Sodium | 153 | $2,784 |
| Atorvastatin Calcium | 186 | $2,484 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 68 | $2,332 |
| Duloxetine Hcl | 54 | $2,111 |
| Losartan Potassium | 131 | $2,073 |
| Lisinopril | 163 | $1,833 |
| Omeprazole | 128 | $1,730 |
| Bupropion XlBupropion Hcl | 40 | $1,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $103 | $37,33235 claims |
| GSKTrelegy Ellipta | $447 | $29,94337 claims |
| PfizerEliquis | $79 | $24,99020 claims |
| Novo NordiskOzempic | $223 | $15,14014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,657 family providers in Michigan.
Other family in Interlochen
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.